Gilead Sciences, Inc. announced that it will expand its access initiatives for AmBisome® (amphotericin b liposome for injection 50 mg/vial) to address the urgent need for treatment of cryptococcal meningitis in 116 low- and middle-income countries.
The expansion, done in collaboration with Unitaid, builds upon Gilead’s long-standing efforts to offer AmBisome at steep discounts to the World Health Organization (WHO) and other public-sector agencies for the treatment of visceral leishmaniasis.
Read the full article on the Gilead webiste.
